Publicly-traded company Cymabay Therapeutics, Inc. (NASDAQ:CBAY) had a closing price of $8.40 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $13.83, this means that the stock is underpriced by 39.262%. In the past 52 weeks the company’s stock price has moved within the range of $1.46 to $9.40.
This particular stock’s 5-day moving average is 8.63, its 20-day moving average is 8.65 and its 100-day moving average is 7.23. Cymabay Therapeutics, Inc. (CBAY) currently has 43860 shares outstanding, which means that its market capitalization is $345.45M.
What Does Wall Street Say about Company?
When considering a new stock purchase, a lot of investors find out how Wall Street analysts feel about the company before they buy in. You can do this by looking for the average analyst rating on the company’s stock. At the moment, the average analyst rating for CBAY is Moderate Buy. Out of 7 total analysts who were surveyed, 1 rated it a Moderate Buy, 0 rated it hold, and 6 rated it a Strong Buy.
Three months ago, on the other hand, the average analyst rating for Cymabay Therapeutics, Inc. (CBAY) was a Moderate Buy – from a survey of 4 analysts. Of the analysts who provided ratings, 0 rated the company a Hold, 1 rated it a Moderate Buy, and 3 rated it a Strong Buy.
Understanding Profitability at Cymabay Therapeutics, Inc. (CBAY)
Having a look at a company’s recent Earnings per Share (EPS) performance is a useful way of understanding its profitability. In the most recent financial results released by Cymabay Therapeutics, Inc., for the quarter ending on 2017-09-30, the company posted EPS of -0.21. The average estimate of Wall Street analysts had projected -0.19.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.13, compared to -0.3 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 4 analysts is 2.5 million – compared to $0 posted in the year-ago period.